Publications by authors named "Bernardo Amadeo Leone"
Article Synopsis
- The study investigates how the pattern of metastatic spread in male breast cancer affects overall survival, as this has been well-established in women but not understood for men.
- Data from the SEER database involving 250 male patients with newly diagnosed metastatic breast cancer between 2010 and 2017 revealed different median overall survival rates based on the metastatic pattern, with bone-only metastases associated with the longest survival.
- The findings indicate that specific factors, such as tumor subtype and the presence of brain metastases, significantly influence survival outcomes, highlighting that brain metastases lead to a significantly poorer prognosis, particularly in younger patients.
Article Synopsis
- The study focuses on women diagnosed with brain metastases at the same time as breast cancer, which is a rare and complex situation.
- In the analysis of 740 patients, the median overall survival was found to be 10 months, with only 20.7% surviving at 3 years; tumor subtype significantly influenced survival rates.
- Key findings indicated that triple-negative breast cancer had the shortest median survival of 6 months, while the HR+/HER2+ subtype had the longest, at 22 months; additional factors affecting survival included age, type of tumor histology, presence of liver metastases, and marital status.
Breast cancer is a systemic disease rather than an anatomical process.
Breast Cancer Res Treat
February 2017
Article Synopsis
- The study analyzed the impact of different metastatic patterns (MP) on overall survival (OS) in women with stage IV breast cancer diagnosed initially, along with other biological and clinical factors.
- A total of 9,143 patients were evaluated, revealing significant differences in median OS based on MP, with bone-only metastases showing the best survival rates.
- Key prognostic factors influencing OS included older age, black race, tumor grade, type (triple-negative), and marital status, which could help guide treatment decisions for patients new to therapy.
Article Synopsis
- Male breast cancer (MaBC) is not well understood, especially regarding the treatment and outcomes for early-stage patients; this study analyzed characteristics, treatments, and survival rates of men with early-stage MaBC.
- The study included 1263 men diagnosed between 1988 and 2012, showing a 5-year overall survival (OS) rate of 85.1%, with older age, higher tumor grades, lack of surgery, and no lymph node examination correlating with poorer outcomes.
- Findings suggest that while men with early MaBC have generally good survival rates, there is a need to reconsider the high rates of mastectomy and extensive lymph node examination since breast conservation and fewer lymph nodes examined yield similar survival rates.
Adjuvant systemic therapy in older women with breast cancer.
Breast Cancer (Dove Med Press)
August 2016
Breast cancer in the elderly is an increasing clinical problem. In addition, ~60% of deaths from breast cancer occur in women aged 65 years and older. Despite this, older women with breast cancer have been underrepresented in clinical trials, and this has led to less than optimal evidence to guide their therapy.
View Article and Find Full Text PDFThe human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent maytansine.
View Article and Find Full Text PDFPrognostic factors in male breast cancer: a population-based study.
Breast Cancer Res Treat
April 2016
Article Synopsis
- The study investigated prognostic factors in male breast cancer (MaBC) by analyzing data from 2992 patients diagnosed between 2003 and 2012.
- Results showed that most MaBC cases were ductal, hormone receptor-positive, and early-stage, while grade I tumors were rare.
- Key findings indicated that older age, higher tumor grades, advanced disease stage, lack of surgery or radiotherapy, ER negativity, and being unmarried were linked to shorter overall survival.
Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10-16 % of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated with an increased incidence of brain metastases. Unfortunately, patients who develop brain metastases tend to have poor prognosis with short overall survival.
View Article and Find Full Text PDFArticle Synopsis
- - The study aims to assess the characteristics and prognostic implications of different tumor subtypes in male breast cancer (MaBC), specifically analyzing data from 960 patients recorded between 2010 and 2012.
- - Patients were categorized into four subtypes based on hormone receptor (HR) and HER2 status, revealing that triple-negative (TN) patients tended to be younger and had poorer outcomes compared to other subtypes.
- - Univariate and multivariate analyses showed that factors like HER2 positivity, tumor stage, and being older significantly impacted overall survival (OS), emphasizing that tumor subtype plays a vital role in prognosis alongside age and stage.
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
José Pablo Leone Julieta Leone Carlos Teodoro Vallejo Juan Eduardo Pérez Alberto Omar Romero Bernardo Amadeo Leone
Breast Cancer Res Treat
January 2014
Article Synopsis
- * After analyzing data from 126 patients over a median follow-up of 4.5 years, the two chemotherapy regimens exhibited similar objective response rates and survival outcomes, with no significant differences in disease-free or overall survival.
- * The study found that the number of pathologically involved lymph nodes was the strongest predictor of survival, and while both regimens were tolerated, CMF had more severe blood-related side effects, while FAC was linked to more hair loss.